Contact
Please use this form to send email to PR contact of this press release:
Clinical Data Abstract Presentation; IP Portfolio of 9 Patents; Phase 3 Cancer Treatments: RenovoRx NASDAQ: RNXT $RNXT
TO:
Shaun Bagai, CEO
RenovoRx, Inc.
+1 650-284-4433